Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444165 · ClinicalTrials.gov registry record · Phase 3
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT06444165 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 55 participants.
The verdict
NCT06444165, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.
Interventions
- DRUG Lebrikizumab Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06444165
The ClinicalTrials.gov registry entry for NCT06444165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab Pen is the first listed.
NCT06444165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06444165 about?
NCT06444165 is a clinical study titled "Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis". The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This st...
What is the current status of trial NCT06444165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2024-06-04. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT06444165?
The interventions under investigation include: Lebrikizumab Pen (DRUG).
Who is sponsoring clinical trial NCT06444165?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.